Related Experiment Video
Updated: Jan 16, 2026
10:33
Generation of Alginate Microspheres for Biomedical Applications
Published on: August 12, 2012
21.7K
Injectable Cryopreservable Alginate-Gelatin Microbeads for Pro-Angiogenic Cell Therapy
Francesco Touani Kameni1,2, Sara Badr1,3, Yohann Vigouroux1,3
1Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC H2X 0A9, Canada.
ACS Biomaterials Science & Engineering
|October 4, 2025
Summary
Researchers developed oil-free microbeads to improve mesenchymal stromal cell (MSC) therapy for ischemic tissues. These injectable, cryopreservable alginate-gelatin microbeads enhance MSC survival and paracrine function, showing promise for clinical applications.
Area of Science:
- Biomaterials Science
- Cell Therapy Engineering
- Tissue Engineering
Background:
- Mesenchymal stromal cell (MSC) therapy faces challenges in cell survival, retention, and paracrine function for ischemic tissues.
- Developing clinically transferable and storable MSC delivery systems is crucial for therapeutic efficacy.
Purpose of the Study:
- To develop an oil-free, injectable, and cryopreservable biomaterial microbead system for encapsulating MSCs.
- To optimize the alginate-gelatin (ALG-Gel) microbead formulation for enhanced MSC viability, function, and stability.
Main Methods:
- An air-assisted coaxial system was used to create oil-free ALG-Gel microbeads encapsulating MSCs.
- Microbead characteristics (size, injectability, mechanical properties, stability) were evaluated at varying gelatin concentrations.
- MSC viability, vascular endothelial growth factor (VEGF) release, and paracrine function were assessed in vitro, pre- and post-cryopreservation.
Main Results:
- Oil-free ALG-Gel microbeads (400-500 μm) were successfully fabricated with good injectability and mechanical stability.
- The ALG-Gel3% formulation demonstrated superior MSC survival and wound closure rates compared to ALG alone.
- Cryopreservation impacted mechanical strength, cell survival, and VEGF release, but cell viability remained >80% post-thaw, with retained pro-angiogenic potential.
Conclusions:
- Oil-free, injectable, and cryopreservable ALG-Gel microbeads offer a promising platform for enhancing MSC therapy safety and efficacy.
- Further optimization of cryopreservation protocols and in vivo validation are necessary to confirm therapeutic potential in ischemic models.
